由于Q3的强劲结果以及2025年的更新预测,ANIP库存猛增了13.6%。 ANIP stock jumped 13.6% on strong Q3 results and upgraded 2025 forecasts.

ANI制药公司(ANIP)的股份在2026年1月12日猛增13.6%,此前报告Q3成果强劲,收入2.114亿美元(高于年均53.1%),经调整的EPS为1.80美元,超过预期。 ANI Pharmaceuticals (ANIP) shares surged 13.6% on January 12, 2026, after reporting strong Q3 results with $211.4 million in revenue—53.1% above year-ago levels—and adjusted EPS of $1.80, exceeding expectations. 该公司提高了2025年全年指导,预测EPS为6.98美元至7.35美元,收入为8.18亿美元至8.43亿美元,均高于先前的预测。 The company raised its 2025 full-year guidance, projecting EPS of $6.98 to $7.35 and revenue of $818 million to $843 million, both above prior forecasts. 分析师维持“机动购买”共识评级,目标为102.14美元。 Analysts maintain a “Moderate Buy” consensus rating with a $102.14 target. 股票交易额为84.83美元,仍然低于52周的最高值98.81美元。 The stock, trading at $84.83, remains below its 52-week high of $98.81.